By Ben Glickman
Biofrontera is being sued by Sun Pharmaceutical, which alleges the company improperly promoted its Ameluz product.
The Woburn, Mass.-based dermatology-focused biopharmaceutical company said in a Tuesday regulatory filing it had been served the complaint, which was filed by Sun and connected companies on Sept. 13.
Biofrontera denies the claims and “intends to defend these matters vigorously.”
The lawsuit alleges Biofrontera committed breach of contract and unfair trade practices and violated the Lanham Act, a trademark law.
“All claims stem from allegations that Biofrontera has promoted its Ameluz product in a manner that is inconsistent with its approved FDA labeling,” Biofrontera said in the filing.
The case will be heard in the U.S. District Court for the District of New Jersey.
Write to Ben Glickman at [email protected]
Read the full article here